In collaboration with:

Royal College of Physicians, London, October 21st, 2014

A gathering of the world’s thought leaders in medicine’s adaptive pathways to patients (MAPPs).

Topics Include:

• How can Europe proceed in the implementation of new development pathways and evidence generation to improve the access of needed new therapies to patients?
• What are the current best practices, successes, and opportunities for the integration of patient data and analytics to improve patient outcomes and identify new medicines?
• How can IMI2’s efforts and programmes under Horizon 2020 help European patients and healthcare providers?

Building on the EMA’s pilot project in adaptive pathways and the UK Government’s Support of a breakthrough designation, IMI, NewDigs and EFPIA will host this international conference to outline research and innovation in adaptive clinical pathways and patient data usage.

Featuring:

Edward Abrahams, President, Personalized Medicine Coalition	Ifty Ahmed, CEO, Pow Health	Mohammad Al-Ubaydli, CEO, Patients Know Best®
James Anderson, Director of EU Industry & External Partnerships, GSK	Andrea Beyer, Expert Benefit Risk Assessment	Richard Barker, Director, CASMI
Jack Bowman, CEO, Handle my Health	Finn Børlum Kristensen, Executive Director, EUnetHTA	Helmut Brand, President, International Forum Gastein
Wendy Currie, Editor in Chief, Health Policy & Technology Audencia, France	John Crawford, Healthcare Industry Leader, IBM Europe	Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency
Laura Esserman, Breast Cancer Center Director (I-Spy), University of California San Francisco	Gary Finnegan, Journalist, Editor and Author	George Freeman, Parliamentary Under Secretary of State for Life Sciences, UK Government
Pat Furlong, Founding President and CEO, Parent Project Muscular Dystrophy	Sarah Garner, Associate Director, Research and Development, National Institutes of Clinical Excellence	Michel Goldman, Executive Director, IMI
Jeremy Haigh, European Chief Operating Officer, Research & Development Amgen Ltd.	Joel Haspel, Director Strategy & Business Development EMEA, Oracle Health Sciences	Adam Heathfield, Senior Director, Global Health and Value Innovation Center, Pfizer
Ryan Hohman, Managing Director, Policy & Public Affairs, Friends of Cancer Research US	Alastair Kent, Director, Genetic Alliance UK	Faraz Kermani, Senior Editor Europe, Elsevier – The Pink Sheet
Yann Le Cam, CEO, Eurordis	Sandrine Marreaud, Head of Medical and Pharmacovigilance Department, EORTC	Jillian Oderkirk, Senior Analyst, Health Division, OECD
Bettina Ryll, Founder, Melanoma Patient Network Europe	Duane Schulhtess, Managing Director, Vital Transformation	Dr Cornelius Schmaltz, Deputy Head of Unit of the Fighting Infectious Diseases and Global Epidemics unit, European Commission
Nathalie Seigneuret, Senior Scientific Project Manager, Innovative Medicines Initiative (IMI)	Paolo Daniele Siviero, Head of Office Pharmaceutical Policy, Italian Medicines Agency	Olga Solomon, Deputy Head of Unit, DG Health and Consumers, Medicinal products, authorisations – ema (D5), European Commission
Sir Richard Thompson, Immediate Past President, Royal College of Physicians	Richard Torbett, Chief Economist, EFPIA	Marc Trusheim, Visiting Scientist, MIT Sloan School of Management MIT Center for Biomedical Innovation
Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutical Companies of Johnson and Johnson	Andrew Ward, Pharmaceuticals Correspondent, Financial Times	Tim Williams, Head of Research, Clinical Practice Research Datalink (CPRD)
Geoff Wilson, HTA Task Force Leader, COCIR	Stephen Whitehead, Chief Executive, ABPI

This conference is supported by:

Research Partners: